Expertise in
4
conditions

Dr. Glen Weiss

Oncology
Beth Israel Deaconess Hospital
330 Brookline Ave # 2, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
4
conditions
Beth Israel Deaconess Hospital
330 Brookline Ave # 2, 
Boston, MA 

Overview

Glen Weiss is an Oncologist practicing medicine in Boston, Massachusetts.

Dr. Weiss is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Pancreatic Cancer, and Gastrostomy.

He is actively involved in clinical research, co-authoring 126 peer reviewed articles and participating in 9 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in AZ

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO

Locations

Beth Israel Deaconess Hospital
330 Brookline Ave # 2, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Enrollment Status: Recruiting
Publish Date: May 29, 2026
Intervention Type: Drug
Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)
Study Phase: Phase 2
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: May 27, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of M6620 (VX-970) in Selected Solid Tumors
A Phase II Study of M6620 (VX-970) in Selected Solid Tumors
Enrollment Status: Completed
Publish Date: July 07, 2023
Intervention Type: Drug
Study Drug: M6620
Study Phase: Phase 2
A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL
A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL
Enrollment Status: Terminated
Publish Date: May 20, 2022
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab
A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab
Enrollment Status: Terminated
Publish Date: October 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase Ib/II Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
A Phase Ib/II Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Enrollment Status: Terminated
Publish Date: July 02, 2018
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

126 Total Publications

Discovery of Structurally Distinct Covalent KRAS G12C Inhibitor Scaffolds Through Large-Scale In Silico Screening and Experimental Validation.
Discovery of Structurally Distinct Covalent KRAS G12C Inhibitor Scaffolds Through Large-Scale In Silico Screening and Experimental Validation.
Journal: Cancers
Published: March 11, 2026
Similar Doctors
Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (2.7 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Davids is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Davids is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
44
conditions
Expertise in
44
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (2.7 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Jacobsen is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Jacobsen is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
36
conditions
Expertise in
36
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (2.7 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Deangelo is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Deangelo is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Systemic Mastocytosis, Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Glen Weiss

How do I make an appointment with Dr. Glen Weiss?

You can book an appointment with Dr. Glen Weiss by calling their office at 617-667-2100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Glen Weiss a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Glen Weiss is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Glen Weiss specialize in?

While Dr. Glen Weiss is a Oncology, they have specific expertise in Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Glen Weiss participate in research or clinical trials?

Yes. Dr. Glen Weiss has published 126 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Glen Weiss's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Glen Weiss accept my insurance?

Dr. Glen Weiss accepts most major insurance plans, including Blue Cross Blue Shield. We recommend calling the office directly at 617-667-2100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weiss's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile